Avoid · 33/100 · high confidence

JBT MAREL Corp (JBTM) — Council Assessment

🔴 AVOID · Score 33/100 · high confidence

A plausible post-merger integration story priced for flawless execution at 187x FCF, with a near-universal panel finding zero margin of safety at the 52-week high.

As of 2026-06-26. 18 lenses weighed in, 0 abstained. Sources: 6 filings, 15 news, 1 earnings_call.

360 narrative — news & sentiment digest

JBT Marel Corporation (JBTM) — Investment Brief

Management Commentary (Earnings Call: Q4 2025)

Headline Results & Guidance

FY2025 revenue: $3.8B (beat guidance); adjusted EBITDA margin: 15.8% (midpoint of guidance)
Adjusted EPS $6.41, exceeding legacy JBT's 2024 EPS of $6.15 — first-year accretion achieved
Leverage ratio improved to 2.9x (vs. 4.0x at close), beating year-end deleveraging target of 3.0x

FY2026 Guidance (core)

Revenue growth: 5–7% (1% FX tailwind included)
Adjusted EBITDA margin: 17.0–17.5% (145 bps improvement at midpoint)
Adjusted EPS: $8.00–$8.57 (29% YoY growth at midpoint)
Q1 2026 revenue: $920–$740M (sic — likely $920M–$740M range unclear); adj. EBITDA margin 14–15%

Synergies & Integration

Realized $43M cost synergies in 2025 (vs. $85M run-rate exiting year); on track for $150M run-rate by end of 2027
Order synergies: $30M captured in FY2025, with >50% in Q4; conversion to revenue expected in 2026
Synergy savings primarily from SG&A streamlining, public company cost reduction, and supply-base consolidation
Expecting ~$60M YoY synergy benefit in 2026

Tariffs & Pricing

Net tariff headwind: ~50 bps margin impact in 2025 ($43M cost; $15M mitigated; pricing offset partial impact)
FY2026 forecast includes ~$45M higher tariff costs (mostly H1), with expectation of 25–50 bps net drag after mitigation and selective pricing
Supreme Court ruling on reciprocal tariffs noted as "moving target" under assessment

Segment Reporting (New Structure)

Protein Solutions (poultry, initial processing): $1.7B revenue; 20.1% adj. EBITDA margin
Prepared Food & Beverage (downstream, ready-to-eat/drink): $2.1B revenue; 17.2% adj. EBITDA margin
2026 protein solutions revenue growth expected at higher end of 5–7% range; prepared food at lower end
Margin improvement expected in both segments; prepared food seeing slightly larger improvement as FY2025 inefficiencies (AGV tariff impacts) normalize in Q1–Q2 2026

Key Q&A Takeaways

Poultry remains dominant: ~75% of poultry orders go to protein segment; 25% to prepared food & beverage (integrated lines)
Cross-selling acceleration: Customer-focused go-to-market and unified marketing drove integrated solutions (e.g., chicken nugget + hamburger processing lines)
Prepared foods AGV weakness: Tariff impacts hit AGV end market harder than rest of business; expected to clear by early Q2 2026
Supply chain regionalization: Moving parts suppliers from Europe to U.S. (ongoing testing); manufacturing footprint review underway; expect completion by 2027
Capital allocation: Focus on completing integration; targeting 2.0–2.5x leverage before M&A; convertible (issued Sept 2025) expected to be refinanced with revolving facility + operating cash flow by end 2026
Investor Day (March 26, 2026): Further details on strategic growth priorities and updated financial targets promised

Recent Developments

Q1 2026 Results (May 2026): Revenue +10% YoY; adjusted EBITDA margin expanded 210 bps (per Investing.com)
Share Repurchase & Dividend (May 2026): $200M buyback authorization; $0.10 quarterly dividend declared
CEO Insider Sale (March 2026): Brian Deck sold shares (GuruFocus report)
Rebranding Complete: Corporate identity shift to JBT Marel finalized; first integrated booth at IPPE (poultry expo) showcased full solution suite

Bull Narrative

Execution & Synergy Beating

Achieved first-year EPS accretion and beat deleveraging targets; order synergies accelerating ($30M in 2025; >50% in Q4 alone)
Management confident in $150M run-rate synergy by end of 2027; currently ahead of original $75M cumulative revenue synergy target

Poultry Recovery & Secular Tailwinds

Poultry affordability, health perception, and price-cost economics driving robust customer investment; "winning food category"
Backlog position strong; orders in Q4 exceeded $1B; "exceptional strength in orders from protein markets"
Management optimistic on continued poultry investment momentum into 2026

Integrated Solutions Differentiation

Cross-selling (e.g., combined JBT–Marel chicken nugget/hamburger lines) gaining traction; unified go-to-market gaining organizational traction
Scale and complementary portfolios driving customer value; management seeing accelerating ability to capture cross-selling benefits

Financial Momentum

Q1 2026 showed 10% revenue growth + 210 bps margin expansion; FY2026 EPS guidance +29% at midpoint
Margin trajectory: 15.8% (FY2025) → 17.0–17.5% (FY2026); leverage improving to sub-2.9x
Capital deployment flexibility (buybacks, dividends resuming post-integration)

Bear Narrative

Tariff Headwinds Persistent & Uncertain

$43M cost in FY2025; $45M expected in FY2026 (mostly H1) — offsetting organic profit growth
Net drag of 25–50 bps expected even after mitigation; Supreme Court reciprocal tariff ruling creates "constantly moving target"
Supply-chain regionalization still early; U.S. localization not complete until ~2027

Prepared Foods Weakness & AGV Uncertainty

AGV end market hit harder by tariff disruption; weakness in FY2025 Q4, expected to linger into early Q2 2026
Broader prepared foods segment at "lower end" of 5–7% growth range, signaling softer underlying demand outside poultry

Valuation & Share Price Weakness

GuruFocus (June 2026) notes stock down 3.7%, trading $119 vs. GF value of $155 — suggesting market skepticism post-rebranding
CEO insider selling (March 2026) may signal concern about near-term price momentum

Integration Execution Risk

Still "relatively early days" on supply chain optimization; manufacturing footprint realization delayed to 2027
Heavy reliance on poultry recovery; diversified end-market exposure not yet fully proven to drive resilience if poultry slows
Management explicitly stated focus on "completing the integration" before M&A — implies execution still absorbs capital and attention

Pricing Power Limits

Management acknowledges not putting 100% of tariff cost on customer; selective pricing only where market permits
Suggests limited pricing power, especially in prepared foods where competition may be stiffer

Retail Sentiment

Limited direct retail/forum commentary in material provided. News aggregation references (TradingKey, TradingView, Yahoo Finance, GuruFocus) indicate:

Mixed-to-bearish tone post-rebranding; stock weakness noted (3.7% decline by mid-June)
Valuation concerns vs. intrinsic value estimates (GF Value $155 vs. price $119)
Minimal retail enthusiasm reflected; coverage appears primarily analyst- and advisor-driven

No detailed retail forum (Reddit, StockTwits) excerpts available to assess grassroots conviction.

Caveats

Q1 2026 Data Point: Single quarter of 10% growth and 210 bps margin expansion; insufficient to validate full-year 2026 guidance of 5–7% and 145 bps margin expansion. Could reflect pull-forward or unsustainable pace.
Tariff Guidance Opacity: Management acknowledges tariff regime as "moving target"; forecast assumes ~$45M cost, but reciprocal tariff ruling adds uncertainty. Risk of material miss in H2 2026 if policy shifts.
Segment Margin Improvement Claims: Management states "relatively same" margin improvement between segments, with "slightly higher" in prepared foods. Lacks granular breakout; difficult to validate improvement drivers independently.
Supply-Chain Regionalization Timeline: U.S. localization completion pushed to 2027; near-term tariff mitigation may be limited, contradicting some synergy timing claims.
Order Synergies Not Isolated: $30M captured in 2025, but no disclosure of synergy quality (gross margin vs. SG&A benefit) or sustainability post-integration. Conversion timing to FY2026 revenue not locked.
Poultry Concentration Risk: ~75% of poultry orders to protein segment; if poultry investment cycle ends abruptly, company lacks near-term diversification buffer (AGV weakness already noted).
Insider Selling Signal: CEO share sale (March 2026) timing relative to investor day and Q1 results warrants scrutiny — may indicate limited upside view near-term.
Limited Q&A Depth: Call transcript shows management deferring detailed guidance to investor day (March 26). Lack of specificity on 2027 targets, M&A appetite, and long-term margin ceilings.
Press Release vs. Earnings: Most recent news references (May–June 2026) are light on substance; reliance on single call transcript from Feb 2026 limits forward-looking clarity.
Retail Visibility: Minimal retail discussion in feeds; professional opinion dominates. Unable to gauge retail conviction or identify tail-risk retail thesis.

Bottom Line for Council: JBTM delivered on FY2025 integration promises (EPS accretion, deleveraging, synergy capture) and Q1 2026 appears strong. Poultry tailwind and order synergies are real near-term drivers. However, persistent tariff drag, prepared-food softness, and elevated valuation uncertainty (per analyst value estimates) warrant cautious positioning. Proof points for FY2026 full-year execution, supply-chain mitigation progress, and macro poultry trajectory critical before re-rating. Investor day (late March) likely to clarify growth strategy and 2027+ targets — wait for that before material position increase.

Bull case

JBT Marel is executing its Marel integration ahead of schedule: leverage cut from 4.0x to 2.9x (beating the 3.0x target), $43M cost synergies realized toward a credible $150M run-rate by 2027, first-year EPS accretion, and Q1 2026 delivering 10% revenue growth with 210 bps of margin expansion. FY2026 adjusted EPS guidance of $8.00-$8.57 (~29% growth) implies normalized earnings power vastly above depressed GAAP. The business has genuine switching costs, aftermarket service annuity, poultry secular automation tailwinds, and — per the disruption referee — AI is a product tailwind rather than a threat. If synergies fully land and FCF normalizes to $300-400M, the equity could approach fair value.

Bear case

On demonstrated economics, this is a value-destroyer: ROIC of 2.5% sits ~580 bps below an 8.4% WACC, GAAP net income is -$50.5M, FCF is a razor-thin $38.7M (1% margin) yielding a 187x P/FCF, and the DCF produces a NEGATIVE intrinsic value (-$5.64 base, even -$1.52 in the bull case) against a $139 price. The $200M-plus gap between adjusted EPS and actual FCF is a textbook quality-of-earnings flag. The balance sheet is stressed (current ratio 0.976, $1.3B net debt, net debt/FCF >30x). The stock trades at/near its 52-week high with the CEO selling shares, so there is no fear-driven discount — the entire market cap is a bet on multi-year flawless synergy delivery plus a continued poultry capex cycle plus tariff mitigation, all simultaneously.

Dissent — where the council disagrees

The panel is lopsidedly bearish, so the key dissent is the AI/Disruption referee's lone PASS (72) — it argues correctly that this is a physical-infrastructure OEM immune to digital disruption, with AI as a tailwind. That matters because it undercuts any secular-decline short thesis and validates the long-term franchise IS durable. On the other side, the value bloc (Graham 22, Klarman 22, Schloss 18, Greenwald 28, Greenblatt 32) plus the Valuation Referee (28) are unanimous that price exceeds every conservative fair-value estimate. The genuine tension is between the growth/momentum lenses (Druckenmiller, Lynch, Fisher, Mauboussin all WATCH ~48-52) who see a real earnings inflection, versus everyone flagging that the inflection is entirely forward-looking and already priced. Notably NO lens issues a PASS on the investment merits — the highest business-quality vote is Buffett/Munger at WATCH. The disruption referee's 72 is a lens-specific verdict, not an endorsement of the price. That resolves the debate toward Avoid: the moat may be real, but you're paying a heroic multiple for synergies not yet in the cash flows.

Key risks

FCF fails to normalize toward $200M+ — the entire valuation collapses if the adjusted-EPS story never converts to cash
Poultry concentration (~75% of protein orders) means a capex cycle downturn breaks the thesis quickly
Tariff headwind (~$45M FY2026, a 'moving target') and supply-chain regionalization not complete until 2027 keep margins impaired
Balance sheet fragility: current ratio <1.0, net debt/FCF >30x, convertible refinancing due end-2026 in an uncertain rate regime
Large, unexplained GAAP-to-adjusted gap (>$380M in add-backs) — quality-of-earnings risk if amortization/integration costs prove recurring
Stale/inconsistent OCF data (2022 figure) undermines confidence in true current cash generation

Catalysts

Investor Day (March 2026) with updated strategic and financial targets
Continued synergy capture toward $150M run-rate and reaching 2.0-2.5x leverage
FY2026 EPS delivery within $8.00-$8.57 guidance and sustained margin expansion
Convertible refinancing execution by end-2026
Poultry order backlog trends and prepared-foods/AGV recovery in H1 2026

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $-5.64/share vs price $139.3 → -104% (bear $-9.85 · base $-5.64 · bull $-1.52).

Step	Value
Base free cash flow	$39M
FCF growth (yrs 1-5)	12.0% (revenue CAGR)
WACC (β 0.954)	8.4%
Terminal growth	2.5%
PV of explicit FCF	$214M
PV of terminal (residual) value	$795M (79% of EV)
Enterprise value	$1.0B
less Net debt	$1.3B
= Equity value	$-293M
/ Shares (52M) = intrinsic/share	$-5.64

⚠️ intrinsic value diverges >100% from price — treat as indicative; check FCF normalization (lumpy/one-off cash flows)

Short-sell evaluation

🔸 MARGINAL SHORT

On fundamentals the short case is intellectually seductive — negative DCF value, 187x FCF, ROIC below WACC, a huge GAAP-to-adjusted earnings gap, buyback funded against $39M of FCF, and a stock at its 52-week high pricing in flawless execution. The forensic short-seller (42, WATCH) catalogs the classic red flags but explicitly stops short of a short rating because the deterioration is not yet at crisis severity and real deleveraging/momentum are present. This is a valuation/quality-of-earnings short, not a fraud or secular-decline short — and those are dangerous to press against a company beating integration targets with genuine Q1 momentum and buying back stock. Attractive on paper, but the squeeze/momentum and execution-is-on-track risks make it a specialist's short, not a clean one.

Pros (the short could work)

Negative DCF intrinsic value (-$5.64 base) and 187x P/FCF leave enormous downside if FCF normalization disappoints
ROIC 2.5% vs WACC 8.4% — economically value-destructive at current returns
$380M gap between adjusted EPS and GAAP net loss; FCF not confirming the earnings narrative — quality-of-earnings risk
Balance sheet stress: current ratio 0.976, net debt/FCF >30x, convertible refinancing looming end-2026
Stock at 52-week high with CEO insider selling — priced for perfection, negative catalysts (tariff shock, poultry cycle turn) available
Poultry concentration creates a single-cycle break point

Cons (what kills the short)

Integration is beating targets (leverage 4.0x to 2.9x) and Q1 2026 showed 10% growth + 210 bps margin expansion — positive momentum kills shorts
Adjusted earnings power ($8+ EPS guide) could validate the multiple as amortization/integration costs roll off, driving a squeeze
$200M buyback and new dividend provide price support and bullish signaling
Durable physical-equipment moat with switching costs; AI is a tailwind not a threat — no secular-decline vector
Not acutely financing-dependent; no near-term debt wall flagged, leverage falling
Unlimited downside asymmetry against a stock already off its highs and delivering operational beats

Council scorecard

Lens	School	Stance	Score	Conf
AI & Disruption Referee (Christensen-style)	referee	🟢 pass	72	medium
Philip Fisher	growth	🟡 watch	52	medium
Michael Mauboussin	quality	🟡 watch	52	medium
Warren Buffett	quality	🟡 watch	48	medium
Ray Dalio	risk	🟡 watch	48	medium
Stanley Druckenmiller	risk	🟡 watch	48	medium
Peter Lynch	growth	🟡 watch	48	medium
Charlie Munger	quality	🟡 watch	42	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟡 watch	42	medium
Joel Greenblatt	value	🔴 avoid	32	medium
Howard Marks	risk	🔴 avoid	32	medium
Chuck Akre	quality	🔴 avoid	28	medium
Valuation Referee (Damodaran-style)	referee	🔴 avoid	28	medium
Bruce Greenwald	value	🔴 avoid	28	medium
Benjamin Graham	value	🔴 avoid	22	high
Seth Klarman	value	🔴 avoid	22	high
Terry Smith (Fundsmith)	quality	🔴 avoid	22	high
Walter Schloss	value	🔴 avoid	18	high

Member reasoning

AI & Disruption Referee (Christensen-style) — 🟢 pass · 72/100 · medium confidence

JBT Marel is a capital equipment manufacturer for food processing — primarily poultry, protein, and prepared foods automation. The core job it does for customers is designing, manufacturing, installing, and servicing highly specialized industrial machinery (slaughtering, portioning, forming, freezing, conveying lines). This is physical-world automation at industrial scale, not knowledge work or digital intermediation. Christensen-style disruption is most lethal against businesses whose core value is information matching, expertise brokerage, or software-defined workflows — none of which describes the primary value here. That said, several sub-questions deserve explicit adjudication. The obsolescence test: can AI/automation remove the need for JBT Marel? No plausible mechanism exists in the 3-10 year horizon. Customers cannot self-serve a chicken processing line. There is no AI model that replaces the physical equipment. The product is atoms, not bits. The disintermediation test: JBTM is not an intermediary — it is a direct OEM that designs, manufactures, and maintains the machines itself. There is no matching layer to bypass. The moat-under-AI question is more nuanced: JBTM's competitive advantages include (1) deep application engineering know-how embedded in equipment design, (2) installed base with aftermarket service lock-in, (3) proprietary food-processing process knowledge (yields, throughput, hygiene). AI could modestly erode (1) if generative design tools democratize mechanical engineering, but this is a gradual, industry-wide shift that takes decades and JBTM can adopt internally. Points (2) and (3) are strengthened by AI: predictive maintenance, computer-vision-based yield optimization, and digital twins built on JBTM's proprietary installed-base data create a compounding moat — the more machines in the field, the richer the training data. The Q4 2025 earnings call does not name AI displacement as a risk, which is appropriate for this sector. Management frames automation (their own product) as the secular tailwind — food processors are investing in labor replacement, biosafety, and throughput, and JBTM IS the automation. This is the AI tailwind scenario: AI-enhanced sensing, vision systems, and robotics make JBTM's equipment MORE capable and differentiated, raising switching costs and ASPs rather than threatening demand. Hyperscaler capture risk is negligible — Amazon, Google, or Microsoft cannot bundle a poultry deboning machine. Platform risk is low. The cost-side AI benefit is real: JBTM can use AI in its own engineering, service scheduling, spare-parts forecasting, and customer support — driving margin improvement without threatening revenue. The $150M synergy target by end-2027 is partly enabled by AI-driven SG&A consolidation. Key risks that temper the score: (a) JBTM's aftermarket service business has some knowledge-work exposure (remote diagnostics, process consulting) where AI could reduce service call frequency or allow customers to self-diagnose — modest risk to aftermarket attach rates; (b) if AI-native robotics startups (e.g., Figure, 1X, or specialized food-processing robot OEMs) develop general-purpose solutions that undercut JBTM's specialized equipment on price, that is a low-probability but non-zero Christensen disruption vector — the 'good enough' robot from below. Management's silence on this threat is understandable given the long technology gap, but warrants monitoring. Falsifiable indicators: PASS confirmed if JBTM launches AI-augmented equipment lines (vision-guided portioning, predictive maintenance platforms) and service revenue per machine rises; AVOID signal emerges if aftermarket attach rates decline, ASP compression from robotics startups, or if customers cite in-house AI tools reducing reliance on JBTM service personnel. Currently no evidence of the latter. Net assessment: this is a physical-infrastructure business that makes other companies' automation work. AI is a product tailwind and internal efficiency driver, not an existential threat. Score 72 — a clear pass on the disruption lens, held back from higher scores by the modest aftermarket service exposure and the early-stage robotics-from-below risk that cannot be dismissed entirely on a 10-year horizon.

Key points

Physical capital equipment OEM — AI cannot replicate or replace poultry/protein processing machinery; obsolescence mechanism does not exist
Not an intermediary: JBTM designs, manufactures, and services equipment directly; no matching layer to disintermediate
AI is a product tailwind: vision systems, computer vision yield optimization, predictive maintenance, digital twins all run on JBTM-owned installed-base data, compounding the aftermarket moat
JBTM IS the automation product food processors are buying to replace labor; secular demand for food automation is accelerated, not threatened, by AI-era labor cost pressures
Internal AI adoption (engineering, SG&A, service logistics) supports the $150M synergy target and margin expansion trajectory without revenue risk
Hyperscaler platform capture is structurally inapplicable — hardware cannot be bundled into a software subscription

Red flags

Aftermarket service consulting and remote diagnostics have modest knowledge-work exposure — AI could reduce service call frequency or enable customer self-diagnosis, compressing aftermarket attach rates over a 10-year horizon
General-purpose food-processing robotics (AI-native startups with cheaper, more flexible robots) represent a low-probability Christensen 'attack from below' that could erode JBTM's specialized equipment moat if the technology gap closes — no evidence yet but a genuine 10-year watch item
Management does not articulate a proactive AI-in-product roadmap in the Q4 2025 call; silence is defensible given sector, but absence of a digital services / data monetization strategy limits upside from the AI tailwind and leaves the field open to more digitally-aggressive competitors
CEO insider selling (March 2026) does not relate to AI risk specifically, but combined with limited forward visibility on AI product strategy, suggests management is not yet thinking offensively about the AI opportunity

Philip Fisher — 🟡 watch · 52/100 · medium confidence

JBT Marel is a food-processing equipment company formed by the January 2025 merger of JBT and Marel, creating a $3.8B revenue global player in protein and prepared food automation. As a Fisher growth investor, this is a borderline case. The company has real product differentiation (integrated poultry-to-prepared-food processing lines, AGV systems, high-value automation), a genuine secular tailwind in protein automation, and management that delivered on first-year integration promises. However, several Fisher criteria are meaningfully impaired: (1) the 33.7% revenue CAGR is almost entirely acquisition-driven, not organic — the Marel deal transformed the company's scale, not underlying growth; (2) R&D investment data is absent from the fact base, which is disqualifying for a Fisher assessment; (3) operating margin of only 5.0% with a net loss is far below what Fisher demands from 'superior and defended' margins; (4) FCF of only $38.7M on $3.8B revenue (1% FCF margin) signals the business is not yet self-funding its own growth; (5) the 5-7% organic revenue guidance for 2026 is solid but not exceptional for an industrial machinery company post-merger; and (6) CEO insider selling (March 2026) raises a candor/alignment flag Fisher would take seriously. On the positive side: Q1 2026 showed 10% revenue growth with 210 bps margin expansion, order synergies are accelerating ($30M in 2025), the $150M run-rate synergy target by 2027 is credible given early beat, management was candid about tariff headwinds (50 bps net drag, $45M cost in 2026), poultry secular tailwind is real and durable, and the integrated solutions go-to-market (cross-selling chicken nugget + hamburger processing lines) reflects genuine product/market expansion that Fisher rewards. The 2026 adjusted EPS guidance of $8.00-$8.57 (+29% YoY) suggests improving profitability as synergies compound. But Fisher would want to see: R&D spend as % of revenue vs. peers, evidence the product pipeline is self-renewing beyond the merger synergies, margin trajectory toward peers (what are peer margins?), and at least 2-3 years of demonstrated organic growth post-integration before calling this a true compounder.

Key points

Q1 2026: 10% revenue growth + 210 bps margin expansion — first tangible post-merger organic momentum signal
Synergy execution strong: $43M cost synergies in 2025 (ahead of $85M run-rate target); $30M order synergies with >50% captured in Q4
$150M run-rate synergy target by end 2027 is ahead of original schedule — management delivering on promises (Fisher values candor + execution)
Integrated food-processing platform (poultry initial processing through prepared foods) creates genuine cross-sell runway Fisher would appreciate
Adjusted EPS trajectory: $6.41 (2025) → $8.00-$8.57 (2026 guidance) = ~29% growth at midpoint; leverage ratio improved from 4.0x to 2.9x in one year
Poultry secular growth thesis: affordability, health perception, and automation economics are multi-year structural drivers — not a one-cycle story
FY2026 guidance (5-7% organic growth, 145 bps margin expansion) is consistent and management reiterated after Q1 beat

Red flags

Revenue CAGR of 33.7% is almost entirely Marel-acquisition-driven — no evidence of sustained organic growth at Fisher-grade rates pre-merger
R&D spending data ABSENT from fact base — Fisher cannot evaluate product pipeline investment without this; critical missing data
Operating margin of only 5.0% and net loss of -$50.5M in 2025 — far below Fisher's 'superior and defended margins' standard for a durable compounder
FCF of only $38.7M on $3.8B revenue (FCF margin 1.0%) means the business is not self-funding; DCF intrinsic value is deeply negative (-$5.64/share base case), indicating current profitability does not support the $139 stock price
CEO Brian Deck insider sale (March 2026) — Fisher weighs management alignment heavily; selling near investor day raises integrity questions
Tariff headwinds ($45M cost, 25-50 bps drag in 2026) are persistent and management admits a 'constantly moving target' — not Fisher-style pricing power
Current ratio of 0.976 (below 1.0x) and price-to-FCF of 187x indicate financial fragility inconsistent with a self-funded growth compounder
Prepared foods segment weakness (AGV end market) and poultry concentration (~75% of protein orders) reduce diversification Fisher typically demands in a mature platform

Michael Mauboussin — 🟡 watch · 52/100 · medium confidence

JBTM (JBT Marel Corp) is a legitimate industrial franchise in food-processing equipment, but the expectations-investing and ROIC-vs-WACC scoreboard raises real concerns at the current price. Starting with the scoreboard: reported ROIC of 2.52% vs. WACC of 8.38% — a deeply negative spread of roughly -580 bps. Even granting that this is a merger-integration year with elevated amortization, M&A costs, and one-time charges suppressing reported returns, the current spread is not merely thin but substantially negative. The DCF intrinsic value is -$5.64/share (even in the bull case -$1.52), against a market price of $139.30 — the valuation model implies the market is paying for a very substantial future improvement in FCF generation that does not yet exist in the financials. Free cash flow of only $38.7M on $3.8B revenue (FCF margin ~1.0%) and operating cash flow data point apparently reflecting a 2022 figure ($142M) rather than a current merged-entity number — the fact base is materially incomplete on normalized FCF. Price-to-FCF of 187x is extraordinary and only defensible if FCF expands dramatically. The expectations embedded in the $139 price require: (1) sustained synergy capture reaching the $150M run-rate by end-2027, (2) margin expansion from 15.8% EBITDA to significantly higher levels, (3) FCF normalization well above current $38.7M (perhaps 5-8x current FCF over 3-4 years), and (4) continued poultry investment cycle strength. These are achievable in the bull case but represent right-tail outcomes relative to industrial M&A base rates — most large industrial combinations underdeliver on synergy timing and face integration drag longer than expected. On moat assessment: the moat is NARROW-to-MODERATE. The combined JBT-Marel entity has genuine switching costs (installed base of capital equipment creates long-term service revenue streams; food processors face high procedural and financial switching costs when changing core processing lines) and some supply-side scale in specialized food-processing machinery. The integrated protein-to-prepared-foods solution capability (combined line selling) is a real differentiation that neither legacy company had standalone. However, there is no network effect, IP moat appears moderate (not patent-cliff-level protection), and brand pricing power is constrained — management explicitly acknowledges they cannot pass 100% of tariff costs to customers, suggesting limited pricing power in prepared foods. The moat is stable-to-strengthening IF cross-selling accelerates as guided, but not yet demonstrated at scale. Capital allocation judgment: the Marel acquisition was transformative and levered the balance sheet to 4.0x (now 2.9x) — management is executing the deleveraging ahead of schedule, which is a positive process signal. The $200M buyback authorization at current prices (187x FCF) is questionable from a capital allocation standpoint — buying back stock at these multiples when FCF is thin is unlikely to create value. Adjusted EPS of $6.41 (FY2025) growing to $8.00-$8.57 guided (FY2026) looks more encouraging, suggesting normalized earnings power is substantially above reported GAAP (net loss of -$50.5M). The gap between GAAP and adjusted earnings is wide, which warrants scrutiny of what is being excluded. Q1 2026 results (10% revenue growth, 210 bps margin expansion) are a genuine positive data point but represent one quarter. Probability distribution: Bull (~25% probability) — synergies fully realize on schedule, poultry cycle extends, prepared foods recovers, FCF normalizes to $400M+ by 2028, stock re-rates to 20-25x normalized FCF = substantial upside. Base (~45% probability) — synergies partially deliver with 12-18 month delay, tariff drag persists, FCF normalizes to $200-300M by 2028, stock flat-to-modest upside. Bear (~30% probability) — integration complexity extends, poultry cycle turns, tariff costs escalate, FCF remains below $100M for 2-3 years, stock corrects materially (50%+ downside from current). The fat tail is on the downside: industrial M&A base rates suggest synergy delivery typically lags management timelines by 1-2 years; the negative FCF spread relative to debt means any earnings miss creates balance sheet stress. Key disconfirming evidence would be: failure to reach 2.0-2.5x leverage by end-2026, FCF not normalizing above $200M in FY2026, or order book weakening in protein solutions. The stock is at its 52-week high on the as_of date (noting the price data shows 52w high = 52w low = $139.30, which appears to be a data artifact — the narrative references prices as low as $119 recently). Conviction is medium given data gaps on normalized FCF, the 2022 operating cash flow figure being used in fundamentals, and incomplete segment-level ROIC data post-merger.

Key points

ROIC of 2.52% is deeply below WACC of 8.38%, generating a -580 bps spread; value destruction on reported figures until synergies materialize
FCF of only $38.7M on $3.8B revenue (1.0% FCF margin) creates a 187x price-to-FCF — valuation requires extraordinary FCF normalization
Switching costs (installed capital equipment, long-term service relationships) and nascent cross-sell capability constitute a narrow-to-moderate moat — real but not wide
Synergy execution is ahead of schedule (2.9x leverage vs. 3.0x target; $43M cost synergies in year 1) — management process score is positive
Q1 2026: 10% revenue growth + 210 bps margin expansion is a genuine near-term positive data point
Adjusted EPS of $8.00-$8.57 guided for FY2026 implies normalized earnings power substantially above GAAP loss — gap requires explanation and validation
$200M buyback at 187x FCF is capital allocation that does not pass the Mauboussin test — buying expensive paper when leverage is still elevated
Base rate for large industrial mergers suggests synergy delivery lags management guidance by 12-24 months — outside view warrants discount to bull case

Red flags

ROIC (2.52%) substantially below WACC (8.38%) — currently destroying economic value; requires significant margin expansion to cross break-even
DCF intrinsic value is negative (-$5.64/share base, -$1.52 bull) vs. $139.30 market price — embedded expectations require right-tail outcome
Operating cash flow in fundamentals appears to reflect 2022 ($142M), not the merged 2025 entity — material data gap on true FCF generation
CEO insider selling (March 2026) concurrent with investor day preparation is a mild negative process signal
Net income negative (-$50.5M) with wide GAAP-to-adjusted gap ($6.41 adjusted EPS) — quality of earnings warrants scrutiny
Current ratio below 1.0 (0.976) with $1.47B long-term debt — balance sheet not yet at comfort zone; 2.9x leverage still elevated for this FCF level
Tariff headwind ($45M FY2026 est.) is a 'constantly moving target' per management — tail risk of policy shock not priced
Poultry concentration (~75% of protein orders) creates single-cycle risk with no near-term diversification buffer if investment cycle turns

Warren Buffett — 🟡 watch · 48/100 · medium confidence

JBT Marel is an industrial machinery company serving the food processing industry — principally poultry, protein, and prepared food/beverage. The business model is understandable: design, manufacture, and service processing equipment with a recurring aftermarket/service tail. This is within my circle of competence in a general sense (think See's Candies-adjacent industrial logic — equipment with installed base creating switching costs and aftermarket annuity). However, the current financial profile is troubled by the recency and scale of the Marel acquisition (completed January 2, 2025), which has produced a dramatically transformed entity with negative net income (-$50.5M), anaemic free cash flow ($38.7M on $3.8B revenue — a 1% FCF margin), negative ROE (-1.1%), and ROIC of only 2.5%. These metrics are far from my quality bar. The DCF produces a negative intrinsic value per share (-$5.64 base) anchored on a paltry $38.7M base FCF against $1.3B net debt — a stark illustration that at current FCF, the equity is essentially a call option on synergy delivery, not a durable compounder. Management delivered first-year EPS accretion ($6.41 adjusted vs. $6.15 legacy) and beat deleveraging targets (2.9x vs. 3.0x target), which is genuinely encouraging. The $150M synergy run-rate target by 2027 and Q1 2026 showing 10% revenue growth with 210 bps margin expansion suggest the integration thesis is progressing. But I do not pay for synergies not yet delivered — I pay for demonstrated earnings power. The moat story is plausible: proprietary processing equipment, deep customer relationships, high switching costs (installed base, food safety certifications, downtime risk), and aftermarket services revenue. GuruFocus GF Value of $155 vs. a recent $119 price suggests some third-party value support, but my own normalized owner-earnings test cannot clear the bar given current FCF. Operating income of $189M against $3.8B revenue (5% margin) is thin for a supposed moat business. The CEO insider sale in March 2026 is a minor negative flag. Tariff headwinds ($45M expected in 2026) and supply-chain regionalization not complete until 2027 add execution uncertainty. I would revisit seriously in 18-24 months if FCF normalizes toward $300M+ (consistent with $8+ adjusted EPS guidance trajectory), leverage drops below 2.5x, and operating margins expand toward 10%+. At current economics, this is a watch — the moat is plausible but unproven at scale, and the price asks me to pay for a story rather than a demonstrated record.

Key points

Food processing equipment with installed base creates genuine switching costs and recurring aftermarket revenue — moat logic is sound in principle
Management beat first-year integration targets: EPS accretion achieved, leverage reduced from 4.0x to 2.9x, $43M cost synergies captured vs. $85M run-rate
Q1 2026: 10% revenue growth, 210 bps margin expansion — integration executing ahead of pace
FY2026 guidance of $8.00-$8.57 adjusted EPS implies ~29% growth; if achieved and sustainable, normalized earnings power is materially higher than current GAAP shows
$200M buyback and $0.10 quarterly dividend declared — management signaling confidence and beginning capital return
Revenue CAGR of 33.7% over 3 years (acquisition-driven) and poultry secular tailwinds provide top-line support

Red flags

Current FCF of $38.7M on $3.8B revenue (1% margin) is completely inadequate — cannot underwrite intrinsic value at current normalized earnings
Negative net income (-$50.5M), negative ROE (-1.1%), ROIC of only 2.5% — far below my 15%+ sustained ROE requirement
DCF intrinsic value is negative (-$5.64/share) because $1.3B net debt dwarfs current FCF generation; equity value depends entirely on synergy delivery
Operating margin of only 5% for an equipment company with supposed pricing power is a red flag — thin margins suggest limited moat or heavy integration disruption costs
Current ratio below 1.0 (0.976) signals balance sheet stress; current liabilities exceed current assets
CEO Brian Deck sold shares in March 2026 — insider selling at this early integration stage warrants scrutiny
Tariff headwinds ($45M in 2026) create persistent drag; supply-chain mitigation not complete until 2027, limiting near-term margin recovery
Heavy reliance on poultry cycle recovery; AGV/prepared food weakness already visible; concentration risk if poultry capex cycle turns
Acquisition-transformed entity with limited track record as a combined company — I do not pay for turnaround stories, I pay for proven earning power

Ray Dalio — 🟡 watch · 48/100 · medium confidence

JBT Marel (JBTM) is a post-merger industrial machinery company serving food processing end-markets — a legitimate Dalio lens target given its leveraged balance sheet, rate sensitivity, capex-cycle exposure, and macro-regime dependencies. The company presents a mixed picture: it has genuine geographic diversification and operates in non-discretionary food infrastructure, but its near-term financial structure is fragile by Bridgewater standards, the FCF base is alarmingly thin relative to valuation, and the business sits at a classically vulnerable point in the post-acquisition debt cycle. The food processing machinery space has some regime robustness (food demand is inelastic), but the EQUIPMENT investment cycle is highly pro-cyclical and credit-dependent — customers invest in new processing lines when credit is cheap and capex ROI is compelling. In a stagflation or deflationary bust, customers defer equipment spending even while food consumption holds. The balance sheet post-Marel acquisition is the dominant risk: net debt of ~$1.3B against FCF of only $38.7M implies a net debt/FCF ratio of ~33x — catastrophically thin coverage. EBITDA coverage is more manageable (operating income $189M, but adjusted EBITDA reportedly ~$600M based on 15.8% margin on $3.8B), implying net debt/EBITDA of roughly 2.2–2.9x (management cites 2.9x). Leverage is declining but the refinancing risk and rate environment deserve scrutiny. The $200M buyback authorization while FCF is only $39M and debt is $1.47B long-term signals either confidence in improving cash generation or a misallocation of scarce capital under a higher-for-longer rate regime. The DCF model produces a deeply negative intrinsic value (-$5.64/share base) using current FCF as the base — a critical red flag even acknowledging normalization potential. The 12% FCF growth assumption used by the DCF referee is derived from the revenue CAGR and may be overstated given merger distortions. The business does earn points for: (1) food-system criticality providing some recession resistance in revenue, (2) genuine global revenue diversification (European heritage from Marel, U.S./Asia exposure), (3) inflation pass-through emerging through selective pricing, (4) synergy execution ahead of schedule reducing some integration risk. However, the single-regime vulnerability (equipment capex only thrives when growth is rising and credit is available), thin current FCF, floating/short-duration refinancing risk on the convertible (issued Sept 2025, noted for refinancing by end-2026), CEO insider selling, and tariff uncertainty create a profile that would perform poorly in Dalio's stagflation or deflationary deleveraging regimes. Regime robustness is partial at best — revenue holds in all regimes, but EBITDA and FCF compress sharply in capex-down cycles. The price at 52-week high and P/FCF of 187x means valuation assumes current-regime continuity with no cushion.

Key points

Food processing end-market provides inelastic REVENUE demand across regimes, but EQUIPMENT investment is highly pro-cyclical — customers defer capex in credit contraction or stagflation
Net debt ~$1.3B vs. FCF $38.7M implies net debt/FCF ~33x; even net debt/adjusted EBITDA at 2.9x is high for a capital-cycle-exposed industrial in a higher-for-longer rate environment
Geographic diversification is genuine: Marel brought European, Asian, and LatAm exposure alongside JBT's U.S. base — scores positively on Dalio's 'shifting world order' diversification criterion
Synergy execution ahead of schedule ($43M realized vs. $85M run-rate exiting 2025; targeting $150M by end-2027) suggests operational improvement that could rebuild FCF materially, but this is forward-looking
Q1 2026 showing 10% revenue growth and 210 bps margin expansion is encouraging; FY2026 adjusted EPS guidance of $8.00–$8.57 (29% YoY growth) implies significant FCF normalization if achieved
Convertible debt refinancing expected by end-2026 using revolving facility + operating cash flow — creates a near-term maturity event in a potentially higher-rate environment
Tariff drag ($45M expected FY2026) represents a real cost inflation headwind with limited pass-through ability — management explicitly states selective pricing only, implying weak inflation pass-through in prepared foods
$200M buyback against $38.7M current FCF and $1.47B long-term debt is aggressive capital allocation that reduces balance sheet resilience
Leverage declining from 4.0x at close to 2.9x in one year demonstrates management execution capability and commitment to deleveraging as priority

Red flags

DCF intrinsic value is deeply negative (-$5.64/share base, -$9.85 bear) against $139 price — even with normalization caveats, this screams valuation that assumes regime continuity with zero margin of safety
Current FCF of $38.7M on $7.25B market cap (P/FCF of 187x) means any regime shift that delays FCF normalization (e.g., stagflation-driven capex deferral by customers) would devastate the equity value
Floating/short-dated refinancing risk: convertible issued Sept 2025 targeted for end-2026 refinancing — this maturity event coincides with uncertain rate environment and reciprocal tariff Supreme Court ruling
CEO Brian Deck insider selling (March 2026) — a negative signal from the insider with most information about near-term execution risk
Single-regime FCF vulnerability: the business only generates real FCF in rising growth + moderate inflation regimes; stagflation (high tariffs + slowing customer capex) or deflationary bust (credit contraction delaying equipment orders) both compress FCF severely
Pro-cyclical demand dynamic: customer investment in processing equipment is highly correlated to food sector credit availability, commodity margins, and overall capex sentiment — all of which deteriorate in Dalio's 'ugly deleveraging' scenario
Poultry concentration (~75% of protein orders) creates a sector-specific vulnerability; if poultry investment cycle ends abruptly, the diversification across prepared foods is undermined by AGV weakness already visible
No inflation-linked revenue contracts noted in filings; pricing is reactive and selective, not contractual — fixed-cost base and merger integration costs limit margin flexibility in a cost-inflation regime
Current ratio of 0.976 (current assets $1.583B vs. current liabilities $1.622B) — technically working capital deficit signals liquidity tightness; company cannot self-fund a stress scenario without capital markets access

Stanley Druckenmiller — 🟡 watch · 48/100 · medium confidence

JBTM presents a genuine earnings inflection story — FY2025 adjusted EPS of $6.41 beating prior JBT standalone, and FY2026 guidance of $8.00–$8.57 (29% midpoint YoY growth) is the kind of second-derivative acceleration I look for. The Marel integration is ahead of schedule on deleveraging (2.9x vs. 4.0x at close, beating 3.0x target), synergies ($43M realized vs. $85M run-rate exiting 2025, on track for $150M by end-2027), and Q1 2026 showed 10% revenue growth + 210 bps margin expansion. The poultry secular tailwind is real and durable — food processing automation is a multi-year capex wave. However, several Druckenmiller-style requirements are missing or problematic. First, the tape is NOT confirming the fundamental thesis: stock is at its 52-week LOW of $139.3 (the fact base shows high_52w = 170.19, and the price data shows pct_below_52w_high = 0%, which appears to be a data error given the narrative references prices around $119–$139 range; the 52w low of $113.67 vs high of $170.19 means the stock is roughly 18% below its 52-week high and has been in a downtrend). CEO insider selling in March 2026 is a tape warning. Second, the macro/liquidity regime is unclear — no explicit Fed easing tailwind identified; tariff headwinds ($45M expected in FY2026) are a policy drag compressing margins. Third, the GAAP picture is ugly: net income negative $50.5M, FCF only $38.7M on $3.8B revenue (1% FCF margin), and the DCF yields a deeply negative intrinsic value (-$5.64/share base case) because the base FCF is far too thin relative to the $7.25B market cap and $1.47B LT debt. The operating cash flow figure cited ($142.3M) appears to be from 2022, not 2025, making the earnings trajectory hard to read cleanly. Current ratio below 1.0 (0.976) with $1.47B long-term debt adds balance sheet opacity. Fourth, the tariff uncertainty ('moving target' per management) makes the thesis impossible to size with conviction — you cannot define a clean invalidation point when the policy variable is uncontrolled. The prepared foods segment softness and AGV weakness add near-term fundamental noise. This is a 'watch and wait for confirmation' setup: the synergy/earnings inflection thesis is real, but I need the tape to confirm (price making new highs), FCF to normalize significantly (management targets should drive much better FCF in 2026-2027 as integration costs roll off), and ideally a clearer macro tailwind (rate cuts helping capital equipment demand). Not a conviction bet today.

Key points

FY2026 EPS guidance of $8.00-$8.57 represents ~29% YoY growth — the kind of earnings acceleration I want to own
Marel integration ahead of schedule: 2.9x leverage vs. 4.0x at close, beating 3.0x year-end target; $150M synergy run-rate by 2027 on track
Q1 2026: 10% revenue growth + 210 bps margin expansion — early 2026 data point confirms the inflection thesis
Poultry secular tailwind is durable: 'winning food category' with strong order backlog (Q4 orders exceeded $1B); automation capex wave multi-year
$200M buyback authorization and dividend reinstatement signal management confidence in cash generation recovery
Revenue CAGR of 33.7% over 3 years (largely acquisition-driven) creates a large combined entity with scale advantages

Red flags

Tape is NOT confirming the thesis: stock trading well below 52-week high of $170.19, in a downtrend; CEO insider selling March 2026 is a bearish signal
FCF dangerously thin: only $38.7M on $3.8B revenue (1% FCF margin) makes DCF intrinsic value deeply negative (-$5.64 base); cannot size with conviction on opaque cash generation
Tariff headwind ($45M in FY2026) is an uncontrolled policy variable — no clean invalidation point possible when the cost driver is a 'moving target' per management
GAAP net loss of -$50.5M and negative ROE in 2025 — trailing fundamentals still ugly even if forward trajectory improves
Current ratio below 1.0 (0.976) + $1.47B LT debt + $1.47B goodwill-heavy balance sheet creates opacity that makes the directional macro bet hard to manage
Operating cash flow data point ($142.3M) appears to be from 2022, not 2025 — fact base has a data integrity issue that undermines earnings trajectory confidence
No clear Fed/liquidity tailwind identified; tariff policy drag actively works against the thesis rather than the central bank providing a tailwind
Prepared foods segment weakness and AGV end-market disruption signal that the bullish poultry thesis does not uniformly apply across the business

Peter Lynch — 🟡 watch · 48/100 · medium confidence

JBT Marel is an understandable industrial machinery business — food processing equipment for poultry, protein, and prepared foods — explainable in a sentence: it makes the machines that process chickens and ready-to-eat foods at scale, and the Marel merger gives it a global integrated platform. That's a Lynch-friendly story on the surface. But the PEG framework breaks down badly here. Net income is negative (-$50.5M in FY2025), making P/E meaningless (-143x). Adjusted EPS of $6.41 (FY2025) with guidance to $8.00-$8.57 (FY2026) gives a forward adjusted P/E of roughly 16-17x on current price of $139.3. FY2026 EPS growth at the midpoint is ~29% YoY, which would normally produce a PEG near 0.55-0.6 — attractive on a Lynch basis IF the earnings are real and recurring. However, the 29% growth is largely merger-synergy-driven (not organic roll-out expansion), and the base FCF is only $38.7M on a $7.25B market cap, yielding a price-to-FCF of 187x — an alarming number by any measure. Free cash flow margin of 1% on $3.8B revenue is far too thin to trust adjusted EPS without heavy normalization. Revenue CAGR of 33.7% over 3 years is almost entirely acquisition-driven (Marel closed Jan 2025), not the kind of organic unit-expansion story Lynch prizes. The balance sheet carries $1.47B long-term debt and a current ratio below 1.0 (0.976), which is a yellow flag on a post-merger integration. Debt-to-equity of 0.33 looks modest but net debt of $1.3B against paltry FCF means leverage is real. The $200M buyback and $0.10 quarterly dividend are positive capital return signals, but they compete with deleveraging needs when FCF is thin. CEO insider selling (March 2026) is a negative. Poultry concentration (~75% of protein orders) is a concentration risk Lynch would note. The integration story is real — $43M cost synergies in year one, ahead of schedule, targeting $150M run-rate by 2027 — and Q1 2026 10% revenue growth with 210 bps margin expansion is encouraging momentum. This looks more like a turnaround/stalwart crossover than a fast grower: a large-cap machinery stalwart recovering margins post-merger, not a 25% organic EPS compounder. At ~17x forward adjusted earnings with 29% near-term growth (synergy-boosted), the yield-adjusted PEG is tempting, but the FCF gap, integration execution risk, tariff headwinds (~$45M expected in 2026), and GAAP losses make this a 'watch' — interesting but not yet provably earning the growth multiple.

Key points

Forward adjusted P/E ~16-17x with FY2026 EPS guidance implying ~29% growth gives an apparent PEG near 0.55 — optically attractive but driven by merger synergies, not organic unit expansion
Q1 2026 showed 10% revenue growth and 210 bps EBITDA margin expansion — real execution momentum
Marel merger achieved first-year EPS accretion and beat deleveraging target (2.9x vs. 3.0x target) — management executing well on integration
$150M synergy run-rate target by end-2027 with $43M already captured in 2025 — credible roadmap
Business is understandable: makes food processing equipment, dominant in poultry, expanding to prepared foods — Lynch-friendly sector
$200M buyback and dividend initiation signal management confidence in FCF normalization

Red flags

GAAP net income is negative (-$50.5M); FCF of only $38.7M on $7.25B market cap yields price-to-FCF of 187x — the 'adjusted EPS' story depends heavily on add-backs that real Lynch analysis would discount
Revenue CAGR of 33.7% is almost entirely Marel acquisition-driven, not organic unit expansion — this is diworsification risk disguised as growth
Current ratio below 1.0 (0.976) and net debt of $1.3B with thin FCF creates balance sheet fragility during integration
CEO Brian Deck sold shares in March 2026 — insider selling at this juncture is a negative signal
Tariff headwinds: $45M expected in FY2026 (25-50 bps net drag) with supply-chain regionalization not complete until 2027 — undermines near-term margin expansion story
Poultry concentration (~75% of protein orders) means one sector slowdown hits hard; AGV weakness in prepared foods already visible
DCF intrinsic value is deeply negative (-$5.64/share base case) due to minimal FCF base — the valuation depends entirely on margin normalization playing out as management projects

Charlie Munger — 🟡 watch · 42/100 · medium confidence

JBT Marel is an understandable industrial machinery business serving the food processing sector — squarely within a definable circle of competence. I can explain the unit economics in a paragraph: the company makes capital equipment and aftermarket services for protein and food processing, sells recurring service contracts, and is attempting to leverage a combined JBT-Marel platform to cross-sell integrated lines. The business model is not opaque. However, quality investing demands honest answers to several uncomfortable questions, and the numbers here give me serious pause. ROIC at 2.5% is a catastrophe — far below any reasonable cost of capital. Net income is negative ($-50.5M). FCF of $38.7M on $3.8B of revenue is a 1% FCF margin, structurally insufficient. These are not the hallmarks of a great business. The Marel acquisition — closed January 2025 — has massively distorted the balance sheet with $8.2B in total assets against $4.5B in equity, implying enormous goodwill/intangible inflation. The DCF produces a negative intrinsic value (-$5.64/share base case) against a $139 stock price, which is a screaming warning sign even accounting for normalization. Management's adjusted EPS narrative ($6.41 in 2025, guiding $8.00-8.57 in 2026) diverges enormously from GAAP reality, which is precisely the kind of adjustment-heavy accounting I distrust. The $150M synergy target is speculative; the CEO sold shares in March 2026; the current ratio is below 1.0 (0.976). On the positive side: Q1 2026 showed 10% revenue growth and 210 bps margin expansion, the 3-year revenue CAGR is 34% (acquisition-driven), leverage improved faster than guided (2.9x vs. 3.0x target), and the food processing equipment sector does have genuine switching costs and aftermarket stickiness that could constitute a moat if margins normalize. Poultry secular tailwinds are real. But I am paying $7.25B market cap for a business generating $38.7M in free cash flow — a price-to-FCF of 187x. Even if FCF normalizes to $200-300M over three years as synergies materialize, I am paying a heroic multiple today. The inversion test: how does this permanently impair capital? Tariff disruption extends, poultry cycle turns, integration synergies disappoint, and the company carries $1.47B in long-term debt with current liabilities exceeding current assets. That scenario is not far-fetched. This is a fair-to-good business purchased at an unfair price during post-merger chaos. I will watch for evidence of genuine moat in the form of sustained returns on capital and FCF normalization, but I cannot pass at today's price with today's fundamentals.

Key points

Understandable business model — food processing equipment with aftermarket service stickiness and genuine switching costs in installed base
Q1 2026 showed encouraging 10% revenue growth and 210 bps EBITDA margin expansion, suggesting integration thesis progressing
Leverage ratio improved to 2.9x ahead of 3.0x year-end target — management delivering on near-term promises
$150M synergy run-rate by 2027 and $30M order synergies captured in 2025 represent real value creation potential if realized
Poultry as secular growth driver is credible — affordability, health perception, and processing automation demand are genuine tailwinds
Revenue CAGR of 34% over 3 years reflects acquisition scale, not organic growth illusion — combined platform is materially larger

Red flags

ROIC of 2.5% is deeply below cost of capital — this is not a great business by any quality metric I recognize
Net income negative (-$50.5M GAAP) while management promotes adjusted EPS of $6.41 — a massive and suspicious divergence
FCF margin of 1% ($38.7M on $3.8B revenue) is structurally deficient; DCF intrinsic value is literally negative at -$5.64/share
Price-to-FCF of 187x demands heroic normalization assumptions that have not yet materialized — I am being asked to pay for a future that isn't here
Current ratio below 1.0 (0.976) with $1.62B current liabilities against $1.58B current assets — balance sheet fragility
CEO insider selling in March 2026 shortly before Q1 results is not the owner-minded behavior I want to see
Goodwill/intangible bloat from Marel acquisition: $8.2B total assets vs. $4.5B equity implies enormous intangible inflation that could require impairment
Tariff headwinds ($45M projected in 2026) represent a persistent and uncertain drag on what is already thin reported earnings
Operating cash flow period cited as 2022 — data inconsistency raises questions about true current operating cash generation
Supply-chain regionalization not complete until 2027; integration still consuming management bandwidth and capital

Forensic Short-Seller (Chanos/Einhorn-style) — 🟡 watch · 42/100 · medium confidence

JBTM presents a mixed forensic picture: several classic short-seller warning signs are present but not yet at crisis severity. The most glaring red flag is the earnings-vs-cash divergence — the company reported a GAAP net loss of -$50.5M for FY2025 while operating cash flow is cited as $142.3M (but the OCF period is flagged as 2022-12-31, creating a data reliability issue). Free cash flow is a thin $38.7M on $3.8B revenue (1.0% FCF margin), while adjusted EPS of $6.41 implying roughly $330M+ in 'adjusted' earnings — a massive GAAP-to-non-GAAP divergence that demands explanation. The $200M+ gap between adjusted earnings and actual FCF is a textbook Chanos-style quality-of-earnings red flag. The business is a serial acquirer (Marel closed Jan 2025, ~$7B+ deal) with $8.2B total assets but only $167.9M cash and $1.47B long-term debt, current ratio below 1.0 (0.976x), meaning current liabilities exceed current assets. The DCF yields negative intrinsic value (-$5.64/share) versus $139.30 market price, implying the entire equity value rests on the synergy/integration story converting to real cash. Heavy non-GAAP reliance is confirmed: adjusted EBITDA margin of 15.8% and adjusted EPS of $6.41 versus GAAP net loss of -$50.5M and -$143 P/E. CEO insider selling in March 2026 is a governance flag. However, countervailing factors prevent a full short rating: Q1 2026 showed genuine 10% revenue growth and 210bps margin expansion; leverage improved from 4.0x to 2.9x (real deleveraging); $200M buyback announced; and the integration appears on-track per management. The business is not financing-dependent in an acute sense — no near-term debt wall is flagged. The thesis requires verification of OCF data period discrepancy before conviction.

Key points

GAAP net loss of -$50.5M vs. adjusted EPS of $6.41 — implies $330M+ in add-backs, a massive quality-of-earnings divergence requiring forensic scrutiny of what is being excluded
FCF of only $38.7M (1.0% FCF margin) on $3.8B revenue while management touts strong earnings accretion — FCF is not confirming the earnings story
OCF period flagged as 2022-12-31 in the fact base while other metrics use 2025 — data integrity issue that must be resolved; if OCF is indeed depressed vs. 2025 GAAP earnings, this is the core short signal
Current ratio of 0.976x (current liabilities $1.622B > current assets $1.583B) — balance sheet is technically underwater on a current basis post-Marel acquisition
Price-to-FCF of 187x and DCF intrinsic value of -$5.64/share mean the entire $7.25B market cap rests on the synergy and margin improvement narrative converting to real cash flows by 2027
Serial acquirer dynamics: $8.2B total assets financed largely by goodwill/intangibles from Marel deal; ROIC of only 2.52% well below WACC of 8.38% — destroying economic value on reported metrics
CEO Brian Deck sold shares in March 2026 shortly after FY2025 results — insider selling at a post-integration inflection point is a governance flag worth monitoring
Non-GAAP adjusted EBITDA of 15.8% vs. operating margin of 4.99% and net margin of -1.33% — persistent and large GAAP/non-GAAP gap is the defining forensic concern

Red flags

GAAP earnings vs. cash divergence: net income -$50.5M vs. claimed OCF $142.3M (period mismatch flagged) vs. FCF $38.7M — adjusted EPS narrative is unsupported by GAAP or FCF
Massive GAAP-to-adjusted gap: $6.41 adjusted EPS implies ~$333M net income equivalent; GAAP net income is -$50.5M — over $380M in recurring 'adjustments' for a supposedly mature industrial company
ROIC (2.52%) well below WACC (8.38%) — the Marel acquisition is currently destroying shareholder value on economic profit basis
Current ratio below 1.0 signals potential liquidity pressure as integration costs continue
CEO insider selling March 2026 — timing relative to Investor Day and Q1 results warrants Form 4 level scrutiny
Tariff headwinds ($45M FY2026E) are ongoing, not one-time — management framing as temporary but supply-chain mitigation delayed to 2027
Poultry concentration (~75% of protein segment orders) creates single-end-market dependency; if poultry capex cycle turns, thesis breaks quickly
$200M buyback authorization while FCF is only $38.7M and current ratio is below 1.0 — buyback is effectively debt-funded, classic financial engineering signal

Joel Greenblatt — 🔴 avoid · 32/100 · medium confidence

JBT Marel Corporation is a real, operating industrial business — post-merger food processing equipment maker — so my framework applies. However, when I run the two Magic Formula inputs, the stock fails on both axes simultaneously, which is the worst outcome for my methodology.

Earnings Yield (EBIT/EV): FY2025 EBIT was $189.4M. EV = market cap ($7.25B) + long-term debt ($1.47B) + [short-term debt implied by current liabilities structure] - cash ($167.9M). Using the stated net debt figure from the DCF of $1.302B, EV ≈ $7.25B + $1.47B - $167.9M ≈ ~$8.55B (conservatively). EBIT/EV = $189.4M / $8,550M ≈ 2.2%. That is a very low earnings yield — the equivalent of a ~45x EV/EBIT multiple. For context, I want earnings yields of 10%+ to get excited; 2.2% is deep into 'expensive' territory on an enterprise basis.

Return on Capital (EBIT / Net Working Capital + Net Fixed Assets): Net working capital = current assets ($1.583B) - current liabilities ($1.622B) = NEGATIVE ($39M). The company has essentially zero or negative net working capital (current ratio 0.976). Net fixed assets are not precisely broken out from filings excerpts, but total assets are $8.19B with a large goodwill/intangibles component from the Marel acquisition. ROIC as reported is only 2.52%, and operating margin is just 4.99% on $3.8B revenue. The business is not earning high returns on the capital it employs — integration costs, acquisition dilution, and the sheer size of the Marel deal have crushed tangible returns. The massive goodwill/intangibles from the acquisition inflate the denominator and suppress ROIC.

Special Situation Angle: The Marel merger completed January 2025 could qualify as a special situation catalyst — forced selling by Marel shareholders, integration synergies creating value. Management is ahead of deleveraging targets (2.9x vs. 3.0x target) and delivered first-year EPS accretion ($6.41 adj. EPS vs. $6.15 legacy). Synergy run-rate of $150M by 2027 is meaningful. However, this potential is already priced in or more: the stock trades at ~45x EV/EBIT, implying the market has already capitalized the synergy story. There is no forced selling discount here — the integration is public, well-covered, and fully priced.

FCF Quality: Reported FCF of only $38.7M on $3.8B revenue (1% FCF margin) and price-to-FCF of 187x. The DCF model correctly yields a deeply negative intrinsic value given the minuscule normalized FCF base relative to debt burden. Operating cash flow figure cited ($142.3M) appears to be from FY2022, not FY2025, suggesting the current year's cash conversion is genuinely poor. Capex of $103.6M versus operating cash flow not clearly stated for FY2025 leaves FCF quality uncertain, but the $38.7M figure is troubling.

CEO Insider Selling in March 2026 is a negative signal on special-situation alignment. Capital allocation is moving toward buybacks ($200M authorization) and dividends ($0.10/quarter), which is shareholder-friendly but modest relative to the market cap — and arguably premature given 2.9x leverage and incomplete integration.

Bottom line: Bad business metrics (low ROIC, sub-5% operating margins, negative working capital) at an expensive price (2.2% earnings yield). This fails the Magic Formula on both dimensions. The integration story is real but fully priced. I cannot find a margin of safety here.

Key points

EBIT/EV earnings yield of approximately 2.2% (~45x EV/EBIT) — far too expensive on an enterprise basis for my framework
ROIC of only 2.52% reported; operating margin just 4.99% on $3.8B revenue reflects integration disruption and massive goodwill from Marel acquisition
FCF of only $38.7M on $3.8B revenue (1% margin); price-to-FCF of 187x makes the stock expensive even on normalized cash flow
Marel merger completed Jan 2025 is a genuine special situation, but synergy story appears fully priced — no forced-selling discount remaining
Leverage at 2.9x is improving but still elevated; $1.47B long-term debt burdens the EV and limits downside protection
Q1 2026 results (10% revenue growth, 210 bps margin expansion) and FY2026 adj. EPS guidance of $8.00-$8.57 (+29%) suggest operational momentum, but adj. EPS ≠ GAAP/EBIT-based earnings yield

Red flags

Magic Formula double-fail: low ROIC AND low earnings yield simultaneously — the worst combination for this framework
Negative net working capital ($1.583B current assets vs $1.622B current liabilities) implies the business needs capital to operate at scale, not generate it
Massive goodwill/intangibles from Marel acquisition inflate total assets to $8.19B versus $4.46B equity — tangible ROIC is even worse than the 2.52% reported figure
CEO Brian Deck insider share sale (March 2026) reduces confidence in special-situation alignment and near-term value realization
Net loss of $50.5M in FY2025 (GAAP) despite $3.8B revenue; negative P/E ratio reflects real earnings drag from integration, amortization, and restructuring
Operating cash flow data point ($142.3M) appears to reference FY2022, not FY2025, creating uncertainty about true current-year cash generation quality
Tariff headwind of ~$45M expected in FY2026 — persistent drag on margins with limited pricing power acknowledged by management in prepared foods segment

Howard Marks — 🔴 avoid · 32/100 · medium confidence

JBTM is a post-merger industrial machinery company trading at $139.30 — at its 52-week high per the price data provided (though the narrative mentions a recent price around $119, suggesting data inconsistency worth flagging). From a risk-first perspective, the fundamental picture is deeply concerning on several dimensions that matter to me. The DCF intrinsic value is negative (-$5.64/share base case, even bull case -$1.52), driven by critically thin free cash flow ($38.7M on $3.8B revenue — a 1.0% FCF margin). Price-to-FCF of 187x means you are paying nearly 200 years of current free cash generation. The company lost money on a GAAP net income basis (-$50.5M) in 2025. Operating cash flow listed is $142.3M from 2022 (a data anomaly — this appears to be stale, not current-year, which itself is a red flag for transparency). The balance sheet carries $1.47B long-term debt against $167.9M cash, with net debt of roughly $1.3B and a leverage ratio management cites at 2.9x adjusted EBITDA. Current ratio is below 1.0 (0.976), meaning current liabilities exceed current assets — a liquidity stress signal. ROIC is 2.5%, far below any reasonable cost of capital (WACC estimated at 8.38%), meaning the company is destroying economic value at scale right now. The bull narrative is real but entirely forward-looking: $150M synergy run-rate by 2027, margin expansion from 15.8% to 17%+, EPS growing 29% in 2026. But all of this is priced in and then some — the market is capitalizing a flawless integration, synergy realization, and poultry cycle durability simultaneously. The CEO sold shares in March 2026. The pendulum has NOT swung toward fear here; if anything, the stock is at its 52-week high (per price data). Even at the $119 level referenced in news, the stock trades at ~1.9x sales with negative GAAP earnings and near-zero FCF. The margin of safety is nonexistent: the DCF says the equity may be worth zero on current cash flows, and the premium is entirely a bet on future execution. Tariff headwinds ($45M expected in 2026), supply chain restructuring delayed to 2027, prepared foods weakness, and poultry concentration risk create meaningful scenarios where execution slips. In those scenarios, with sub-1x current ratio and 2.9x leverage, the downside is asymmetric to the downside. This is not distressed enough to be interesting from a contrarian perspective, nor is it high-quality enough to justify growth premiums. It sits in the worst zone: moderate risk, high expectations, minimal margin of safety.

Key points

DCF intrinsic value is negative across all scenarios (bear -$9.85, base -$5.64, bull -$1.52); entire market cap is a pure bet on execution and synergy realization
FCF margin of 1.0% and FCF of only $38.7M on $3.8B revenue; price-to-FCF of 187x offers no margin of safety whatsoever
ROIC of 2.5% vs. WACC of ~8.4% — company is destroying economic value; equity premium is completely speculative
Net debt ~$1.3B, current ratio below 1.0 (0.976), leverage 2.9x at close of 2025 — balance sheet fragile if cycle turns or synergies slip
All bull catalysts (synergy, margin expansion, EPS growth) are forward-looking and already appear priced in at current levels; stock at or near 52-week high
$200M buyback authorization while FCF is $38.7M annually — capital allocation is leveraging up relative to actual cash generation

Red flags

Price embeds flawless integration execution, $150M synergy realization, poultry cycle continuation, and tariff mitigation — a consensus-rosy scenario with no room for error
CEO insider sale in March 2026 coinciding with near-52-week-high price is a negative signal
Negative GAAP net income (-$50.5M) and near-zero FCF make this a story stock priced on adjusted metrics management controls
Current ratio below 1.0 signals potential near-term liquidity stress; $1.47B long-term debt creates refinancing vulnerability if credit conditions tighten
Tariff headwind of ~$45M in 2026 is persistent and management admits it is a 'moving target' — scenario risk to margin guidance is real and unquantified
Supply chain regionalization not complete until 2027 — key risk mitigation is 18+ months away, yet valuation assumes smooth execution now
Operating cash flow data point in fact base appears to be 2022 vintage ($142.3M) — raises data quality concern and may overstate actual current cash generation

Chuck Akre — 🔴 avoid · 28/100 · medium confidence

JBT Marel fails on nearly every core leg of the Akre three-legged stool. The business is an industrial machinery manufacturer serving food processing — a capital-intensive, cyclically sensitive sector — that has just completed a large, transformative merger with Marel. The numbers tell a difficult story: ROIC of 2.5%, ROE of -1.1%, net loss of $50.5M on $3.8B revenue, FCF margin of only 1.0% ($38.7M FCF on $3.8B revenue), and price-to-FCF of 187x. The DCF intrinsic value is deeply negative (-$5.64/share base case) because the current FCF base is so thin relative to the enterprise's net debt load of $1.3B. While management delivered on first-year EPS accretion targets (adjusted EPS $6.41) and improved leverage from 4.0x to 2.9x, these are GAAP-adjusted metrics — GAAP net income is negative. The 33.7% revenue CAGR over 3 years is entirely M&A-driven (Marel acquisition), not organic compounding. Operating margin of 5.0% is thin for a franchise business. The company does have genuine assets — specialized food processing equipment, cross-selling synergy potential, exposure to secular poultry tailwinds, and a $150M synergy target — but these are integration promises, not demonstrated compounding economics. CEO insider selling in March 2026 is a yellow flag on management integrity leg. The $200M buyback authorization at current prices ($139/share) when GAAP FCF is only $38.7M annually raises capital allocation questions. Debt-to-equity of 0.33x is not egregious but long-term debt of $1.47B against thin FCF is constraining. This is fundamentally a post-merger industrial integration story, not a compounding franchise.

Key points

ROIC of only 2.5% and ROE of -1.1% — far below Akre's ~20%+ threshold for 'extraordinary business'
FCF of $38.7M on $3.8B revenue = 1.0% FCF margin; price-to-FCF of 187x is extreme for this quality profile
Revenue CAGR of 33.7% is acquisition-driven (Marel merger Jan 2025), not organic compounding
Management delivered adjusted EPS accretion and deleveraging ahead of targets — partial credit on skill
Synergy runway ($150M run-rate by 2027) represents genuine reinvestment potential if executed
Q1 2026 showed 10% revenue growth and 210 bps margin expansion — early integration execution positive
Poultry secular tailwind and cross-selling create a plausible long-term growth story

Red flags

GAAP net loss of $50.5M; adjusted EPS metrics obscure true earnings power — integrity concern re: non-GAAP framing
FCF base of $38.7M is insufficient to support $7.25B market cap or $200M buyback — capital allocation mismatch
DCF intrinsic value negative in all scenarios (bear -$9.85, base -$5.64, bull -$1.52) vs. $139 price — massive overvaluation on current FCF
CEO Brian Deck insider sale in March 2026 shortly after investor day — management alignment concern
Operating margin of 5.0% is not franchise-quality; thin margins with tariff headwinds of ~$45M expected in 2026
Current ratio below 1.0 (0.976) signals near-term working capital pressure uncommon in franchise businesses
Capital-intensive industrial machinery business fails capital-light test; capex $103.6M vs. FCF $38.7M — capex exceeds FCF net of operating cash
Heavy integration execution risk — supply chain regionalization not complete until 2027; manufacturing footprint review ongoing

Valuation Referee (Damodaran-style) — 🔴 avoid · 28/100 · medium confidence

The DCF provided and my own reverse-engineering both point to deep overvaluation. The base-case DCF intrinsic value is negative (-$5.64/share) against a $139.30 market price, driven primarily by the fact that JBTM's normalized free cash flow ($38.7M) is anemic relative to its $7.25B market cap and $1.30B net debt load. The price-to-FCF of 187x is egregious. Even acknowledging that FY2025 FCF is depressed by post-merger integration costs and that adjusted EBITDA of ~$600M (15.8% on $3.8B revenue) is more representative, the implied valuation still demands heroic assumptions. To justify $139.30, I need to back-solve: at 8.4% WACC, to get equity value of ~$7.25B, I need enterprise value of ~$8.55B. Discounting back at 8.4% with a 2.5% terminal growth requires a normalized FCF at Year 5 of roughly $600-700M — that is 15-18x the current reported FCF. Even using adjusted EBITDA as a proxy for potential cash generation (~$600M) minus capex (~$104M) and taxes, I get potential normalized FCF of roughly $350-400M — still requiring 50-75% FCF growth from today to justify terminal value. The FY2026 EPS guidance of $8.00-$8.57 (adjusted) would imply ~$440M adjusted net income, but GAAP net income was -$50.5M in FY2025. The gap between adjusted and GAAP is enormous and must be scrutinized: heavy amortization from the Marel acquisition (large goodwill/intangibles on $8.2B asset base), integration costs, and deal-related charges are real economic costs even if management adjusts them away. ROIC of 2.52% stands far below the 8.38% WACC — growth is actively destroying value at current reinvestment levels. The revenue CAGR of 33.7% (3-year) is almost entirely M&A-driven, not organic, and using it as a FCF growth proxy in the DCF is unjustified. The margin story is plausible in direction (17.0-17.5% adj. EBITDA by end of 2026, $150M synergy run-rate by 2027) but GF Value at $155 vs. the current $119-$139 range shows even generous valuation methodologies struggle to justify current prices. The current price at 52-week high ($139.30) implies no margin of safety whatsoever. Key mitigants: if normalized FCF can reach $300-400M within 2-3 years through synergy realization, the business may approach fair value in the $80-100 range under conservative assumptions, but that requires execution the market is already pricing in. The investment at $139.30 requires the optimistic synergy + margin scenario plus poultry cycle continuation plus successful tariff mitigation — all simultaneously. That is not investing, it is speculating on a perfect outcome.

Key points

DCF intrinsic value is -$5.64/share (negative) against $139.30 price — even heavily caveat-adjusted, the model cannot approach current pricing with reasonable assumptions
ROIC of 2.52% vs. WACC of 8.38% = value-destructive growth; every dollar reinvested in acquisitions at current returns shrinks intrinsic value
FY2025 FCF of $38.7M on $7.25B market cap implies P/FCF of 187x — requires massive FCF normalization that is already priced in
The 33.7% revenue CAGR is almost entirely Marel-acquisition driven; using it as organic growth proxy in DCF is false precision
Adjusted EPS guidance of $8.00-$8.57 implies large GAAP-to-adjusted gap; $50.5M GAAP net loss must be normalized carefully — amortization of acquisition intangibles is a real cost
Synergy path ($150M run-rate by 2027) is plausible but already discounted in market price; upside requires execution above base case
Revenue growth of 5-7% organic plus synergy capture is reasonable but insufficient to close the $139 vs. fair-value gap within a 5-year horizon at sub-3% FCF margin
No margin of safety: stock at 52-week high, implying the market already prices in the bull scenario
GF Value of $155 vs. market price $119-139 suggests even optimistic third-party models barely support current price range

Red flags

ROIC (2.52%) materially below WACC (8.38%) — growth is value-destructive at current economics; must see ROIC converge toward WACC before any DCF produces positive equity value
Negative GAAP net income (-$50.5M) with enormous GAAP-adjusted gap signals heavy amortization drag from Marel deal that will persist for years, suppressing true free cash flow
Current ratio below 1.0 (0.976) and FCF margin of 1.02% indicate near-term cash generation strain despite large adjusted EBITDA numbers
CEO insider selling (March 2026) near 52-week high is a concerning signal when combined with integration complexity
Operating cash flow figure cited in fundamentals ($142.3M) is from 2022 — data inconsistency makes normalization difficult and undermines confidence in FCF trajectory
Terminal value represents 78.8% of DCF enterprise value — model heavily dependent on assumptions beyond 5-year explicit period, maximizing sensitivity to terminal growth and WACC inputs
Price at 52-week high of $139.30 means no margin of safety under any conservative fair-value estimate; investor needs the bull scenario just to break even
Tariff headwind of ~$45M in FY2026 partially offsetting synergy benefit, with supply-chain regionalization not complete until 2027 — execution risk is concentrated in the near term

Bruce Greenwald — 🔴 avoid · 28/100 · medium confidence

Applying Greenwald's EPV framework to JBTM reveals a deeply unfavorable picture. The company is a freshly merged industrial machinery manufacturer (JBT + Marel, completed Jan 2025) with heavily distorted reported financials. My EPV calculation starts with normalized operating earnings: FY2025 operating income of $189.4M on $3.8B revenue gives a 5.0% operating margin — but this is a first-year post-merger figure burdened by integration costs, purchase accounting amortization, and tariff headwinds. Management's adjusted EBITDA margin was 15.8%, implying roughly $600M adjusted EBITDA. However, I must be cautious: the delta between 5% reported and ~16% adjusted is enormous ($427M difference), and without detailed add-back schedules from the filings (which are XBRL-heavy without narrative sections in the provided excerpts), I cannot fully normalize. Taking a conservative middle ground — say 8–9% normalized EBIT margin (stripping out obvious purchase amortization but not accepting every management add-back) — yields roughly $300–340M normalized EBIT. Tax-affecting at ~25% gives NOPAT of ~$225–255M. Capitalizing at the WACC of 8.38% gives EPV of approximately $2.7–3.0B enterprise value, implying equity EPV of roughly $1.4–1.7B (deducting $1.3B net debt), or ~$27–33 per share. The current market price of $139.30 is roughly 4–5x my EPV estimate. Even using management's adjusted EPS guidance of $8.00–$8.57 for FY2026 and capitalizing at WACC (~12x), implied equity value is ~$96–103 per share — still meaningfully below the $139 market price. The stock appears priced for substantial growth AND margin expansion simultaneously, not for earnings power as it stands. Asset reproduction value cross-check: total assets of $8.2B include substantial goodwill and intangibles from the Marel acquisition (the merger added ~$4B+ in intangible assets based on the stockholders' equity vs. net assets structure). Tangible reproduction value is far lower than book. The EPV-to-assets comparison here is unfavorable: EPV << asset carrying value, suggesting either value destruction in the merger premium or that significant synergy realization (the $150M run-rate by 2027) is needed just to justify the transaction, let alone the current equity price. On moat assessment: JBTM does have real competitive advantages — specialized food processing equipment, high switching costs (installed base, service contracts, process integration), and scale in a niche global market (poultry processing especially). Customer captivity is real: once a protein processing line is designed around JBT or Marel equipment, switching is costly. This is a genuine, if modest, franchise. However, the barriers are not impenetrable — European competitors exist, the industry is not oligopolistic enough to sustain returns dramatically above cost of capital over long periods, and ROIC of only 2.5% (per the fact base, admittedly depressed by acquisition goodwill) suggests the merger premium has materially diluted returns. The DCF provided yields negative intrinsic value (-$5.64/share) because base FCF of only $38.7M is laughably small relative to the capital structure — this reflects the reality that actual free cash conversion is poor post-merger (heavy capex, integration costs, working capital). The caveat about FCF normalization is warranted but even normalized FCF well above $38.7M cannot close the gap to $139. Q1 2026 showed 10% revenue growth and 210 bps margin expansion — encouraging, and the synergy story ($43M in 2025, targeting $150M run-rate) is credible given management's early beats. But I must not pay for this growth without a margin of safety in EPV. At $139, I am paying well above EPV for growth that requires (1) full synergy realization over 2+ more years, (2) continued poultry capex cycle, (3) margin expansion from 5% reported to management-guided 17%+, and (4) successful supply-chain regionalization. None of these are in the 'knowable now' column. CEO insider selling in March 2026 adds a minor negative signal. The $200M buyback at these prices, if EPV is well below market, is potentially value-destructive capital allocation.

Key points

EPV estimated at ~$27–33/share (capitalizing normalized NOPAT of ~$225–255M at 8.38% WACC, less $1.3B net debt) versus market price of $139.30 — a roughly 4–5x premium to EPV
Reported operating margin of only 5.0% with a massive 1,080bp gap to management's adjusted EBITDA margin of 15.8% — normalization is genuinely difficult in year-1 post-merger; conservative normalization still yields EPV far below market
Real customer captivity exists (installed base, service integration, switching costs in specialized food processing lines) — franchise elements are present but not strong enough to justify current premium
ROIC of 2.5% (depressed by merger goodwill) signals that acquisition premium has materially diluted returns; sustained above-WACC returns not yet demonstrated
Synergy story ($43M in 2025, $150M run-rate target by 2027) is tracking ahead of plan — but this creates value only if the merger premium was reasonably priced, which appears questionable at current equity levels
Q1 2026 momentum (10% revenue growth, 210 bps margin expansion) is encouraging near-term signal but insufficient to close EPV-to-price gap
Leverage improved to 2.9x (from 4.0x at deal close) — balance sheet trajectory positive, but $1.47B long-term debt remains a real burden on equity EPV

Red flags

Market price of $139 is approximately 4–5x estimated EPV of ~$30/share — nearly the entire valuation premium rests on growth and synergy realization that cannot be conservatively assumed today
Reported FCF of only $38.7M on $3.8B revenue (1.0% FCF margin) means the business is not currently generating meaningful distributable earnings; DCF intrinsic value is negative, corroborating EPV concerns
Serial one-time/adjusted items: the $427M gap between reported and adjusted EBITDA in a single year is a major normalization red flag — cannot verify all add-backs from available filing excerpts
CEO Brian Deck insider selling (March 2026) occurring near investor day and ahead of guidance year is a mild negative signal under Greenwald's framework (management has informational advantage)
EPV << asset carrying value suggests either the Marel merger premium will require years of synergy realization just to break even, or returns will remain below WACC for extended period
Tariff headwind (~$45M expected in FY2026) and supply-chain regionalization not completing until 2027 mean near-term earnings power remains impaired, making normalization even harder
Negative current ratio (0.976) — current liabilities exceed current assets, adding financial flexibility concern to the moat/EPV picture

Benjamin Graham — 🔴 avoid · 22/100 · high confidence

JBT Marel fails virtually every quantitative Graham test. The balance sheet is deeply impaired: current ratio of 0.976 (well below Graham's minimum of 2.0), meaning current liabilities ($1.622B) exceed current assets ($1.583B) — a working capital deficit of ~$39M. Long-term debt of $1.47B massively exceeds the negative working capital, violating Graham's debt-to-working-capital criterion categorically. The P/E ratio is negative (net loss of $50.5M in FY2025), so there is no Graham-valid earnings yield to anchor value. The price-to-book of 1.62x is above Graham's combined P/E × P/B ≤ 22.5 threshold, and with a negative P/E the test fails entirely. Net current asset value (NCAV) = $1.583B current assets minus $8.191B total liabilities = deeply negative (~-$6.6B), meaning the stock trades at an infinite premium to its net-net value — the exact opposite of what Graham requires. The DCF intrinsic value is -$5.64/share (base case) against a $139.30 price, implying negative margin of safety. FCF of only $38.7M on a $7.25B market cap yields a price-to-FCF of 187x, with the DCF noting that current FCF is likely suppressed and the analysis itself flags the divergence. ROIC of 2.52% barely exceeds the cost of capital. The company has a net income loss in FY2025 and operates with only a 5% operating margin — neither demonstrates the earnings stability Graham demands over a multi-year look-back. Dividend was recently initiated at $0.10 quarterly (minimal yield, no long record). CEO insider selling in March 2026 is a further concern. The only partial positives are: meaningful scale ($3.8B revenue), a revenue CAGR of 33.7% (driven by the Marel acquisition, not organic growth), and management's stated synergy delivery — but these are forward-looking narratives, exactly the speculative growth story Graham distrusts. No margin of safety exists by any conservative Graham metric.

Key points

Current ratio 0.976 — fails Graham's minimum of 2.0; working capital is negative (-$39M)
Long-term debt $1.47B vs. negative working capital — catastrophic failure of debt-to-working-capital test
Net income loss of -$50.5M in FY2025; P/E is negative, no valid earnings yield
NCAV deeply negative (~-$6.6B); stock trades at enormous premium to liquidation value
DCF intrinsic value per share: -$5.64 base case vs. $139.30 price — zero margin of safety
Price-to-FCF of 187x on thin $38.7M FCF — no conservative earnings anchor
ROIC of 2.52% — barely above cost of capital, indicative of value destruction post-merger
Dividend initiated only recently; no long track record of uninterrupted payments

Red flags

Balance sheet is impaired: current assets do not cover current liabilities
Negative net income in FY2025 — violates Graham's earnings stability criterion
Price far exceeds every conservative intrinsic value estimate (DCF, NCAV, earnings yield)
Acquisition-inflated revenue CAGR (33.7%) masks organic growth picture; goodwill-heavy balance sheet
CEO Brian Deck sold shares in March 2026 — insider bearish signal
Heavy acquisition-related debt ($1.47B LT debt, $1.3B net debt) with integration risk still unresolved
Tariff headwinds (~$45M in 2026) threaten already-thin margins and FCF generation
P/E × P/B combined test fails entirely due to negative earnings

Seth Klarman — 🔴 avoid · 22/100 · high confidence

JBTM fails virtually every Klarman margin-of-safety criterion. The DCF intrinsic value is negative (-$5.64/share base case), and even the bull scenario yields -$1.52/share, against a current price of $139.30 — a complete inversion of margin of safety. The company is a post-merger integration story trading on optimistic synergy narratives and growth forecasts, not discounted hard asset value. FCF is just $38.7M on $3.8B revenue (1% FCF margin) and $7.25B market cap, implying a price-to-FCF of 187x — there is no cash flow-based floor. The balance sheet offers no comfort: current ratio of 0.976 (current liabilities exceed current assets by $39M), $1.47B long-term debt, and $1.30B net debt against only $38.7M of FCF means the company cannot self-fund debt paydown without prolonged operational improvement. ROIC is 2.5%, well below any reasonable WACC estimate of ~8.4%, meaning the business is destroying economic value. Goodwill and intangibles from the Marel acquisition almost certainly dominate the $8.2B asset base ($4.46B equity on $3.8B revenue implies massive intangible loading); book value of $85.88/share is itself likely impaired by acquisition premiums that won't be recovered in liquidation. The investment thesis rests entirely on: (1) $150M synergy run-rate by 2027, (2) poultry cycle continuation, (3) margin expansion from 5% operating margin today to 17%+ EBITDA, and (4) tariff headwinds clearing — every single one of these is an optimistic forecast, not a downside-protected fact. CEO insider selling in March 2026 is a negative alignment signal. The $200M buyback at 187x FCF destroys value from a Klarman perspective. Q1 2026 momentum (10% revenue growth, 210 bps margin expansion) is real but one quarter of data cannot validate a thesis that requires multi-year execution. GuruFocus GF Value of $155 vs. prior price of ~$119 suggests even bullish outside value estimates show limited upside, and the stock has since rallied to $139 — near the 52-week high — removing even the relative discount. This is a merger integration story priced for success with no margin of safety, elevated leverage, negative economic value creation, and asset backing dominated by intangibles. Klarman would hold cash.

Key points

DCF intrinsic value is -$5.64/share (base) to -$1.52/share (bull) vs. $139.30 price — zero margin of safety, inverted
Price-to-FCF of 187x on $38.7M FCF against $7.25B market cap; FCF margin of just 1% on $3.8B revenue
ROIC of 2.5% versus WACC of ~8.4% — business is destroying economic value at the current operating level
Current ratio of 0.976; current liabilities exceed current assets; net debt of $1.30B vs. $38.7M annual FCF
$8.2B asset base dominated by acquisition goodwill/intangibles from Marel deal; book value floor is illusory in liquidation
Entire thesis depends on $150M synergy run-rate by 2027, poultry cycle, 17%+ EBITDA margins — all optimistic forecasts
Stock at 52-week high ($139.30), removing even relative technical cheapness; CEO selling shares in March 2026

Red flags

No margin of safety: price exceeds every conservative intrinsic value estimate including bull DCF scenario
Value entirely dependent on multi-year synergy execution, poultry cycle continuation, and tariff environment improving
Fragile balance sheet: current ratio <1.0, $1.47B long-term debt, net debt/FCF ratio >33x
ROIC (2.5%) far below WACC (~8.4%) — company is a value destroyer at current economics
Goodwill-heavy asset base (~$4-5B estimated intangibles) means book value/liquidation floor is largely fictional
CEO Brian Deck insider selling (March 2026) signals limited near-term upside conviction by management
Tariff drag ($45M expected in 2026) is a 'moving target' per management — key assumption in thesis cannot be stress-tested reliably
Operating margin only 4.99% — gap to guided 17%+ EBITDA requires flawless multi-year execution with no room for error

Terry Smith (Fundsmith) — 🔴 avoid · 22/100 · high confidence

JBT Marel Corporation fails virtually every criterion in the Fundsmith quality screen. This is an industrial machinery business built through a large debt-funded acquisition (Marel, completed January 2025), carrying substantial leverage, thin cash conversion, negative reported net income, a near-negligible FCF margin of 1%, and ROIC of only 2.5% — far below the cost of capital. The Marel merger inflated the balance sheet with goodwill and intangibles (total assets $8.2B vs. equity $4.5B), added $1.47B in long-term debt, and the combined entity is still in integration mode with synergy realisation deferred to 2027. Operating margin is only 5%, gross economics are not those of a franchise business, and the DCF produces a negative intrinsic value per share (-$5.64 base case) reflecting how little genuine free cash flow the business generates relative to its capitalisation and debt load. The adjusted EPS ($6.41) dressing masks a GAAP net loss of -$50.5M — precisely the kind of non-GAAP reliance Smith flags as a red flag. The business serves cyclical food-processing capex customers (poultry, prepared foods), meaning demand is neither recurring nor truly resilient in the way Smith requires. CEO insider selling further undermines conviction. Q1 2026 momentum (10% revenue growth, 210 bps margin expansion) is noted but insufficient to rehabilitate the fundamental picture: the company must first de-lever, integrate, and prove sustained high-return economics — none of which are yet visible in the numbers.

Key points

ROIC of 2.5% is far below any reasonable cost of capital hurdle (~8-9% WACC per DCF), violating Smith's primary ROCE test
FCF margin of only 1% ($38.7M on $3.8B revenue) with price-to-FCF of 187x — cash conversion is severely impaired
GAAP net loss of -$50.5M vs. adjusted EPS of $6.41 reflects heavy reliance on non-GAAP metrics that Smith explicitly distrusts
Marel acquisition completed via debt creates serial-acquisition roll-up profile Smith avoids; goodwill embedded in $8.2B asset base
Operating margin only 5% with no evidence of durable pricing power or moat-like economics
Revenue CAGR of 34% is acquisition-driven, not organic compounding — inflated by Marel consolidation, not quality reinvestment
$200M buyback authorised while FCF is only $38.7M and net debt ~$1.3B — capital allocation priorities seem misaligned
Debt-to-equity 0.33 understates leverage; net debt/EBITDA ~2.9x (management's own figure) with explicit target of 2.0-2.5x before M&A

Red flags

Serial debt-funded acquisition: Marel deal is archetypal roll-up that Smith openly distrusts
Adjusted vs. GAAP earnings gap: -$50.5M GAAP net income vs. $6.41 adjusted EPS suggests large integration/amortisation charges masking true economics
Negative DCF intrinsic value (-$5.64/share) — market price of $139 implies enormous premium to any reasonable FCF-based valuation
Current ratio below 1.0 (0.976) and negative working capital — liquidity tight for a company in heavy integration
CEO Brian Deck insider selling (March 2026) proximate to Investor Day and Q1 results — adverse signal
Tariff headwinds ($45M expected FY2026) and supply-chain regionalization not complete until 2027 add further near-term cost uncertainty
Capital intensity: $103.6M capex on $38.7M FCF — capex consumes nearly 3x free cash flow, strongly asset-heavy profile
Cyclical end-market exposure (food processing capex) inconsistent with Smith's preference for resilient, recurring-purchase demand

Walter Schloss — 🔴 avoid · 18/100 · high confidence

JBT Marel fails virtually every Schloss criterion. The stock trades at 1.62x book value and the book itself is massively inflated by goodwill and acquisition intangibles from the January 2025 Marel merger — tangible book value is almost certainly deeply negative given $8.19B in total assets against $4.46B equity, with the bulk of that equity representing acquired intangibles/goodwill from a $3.8B revenue company. There is no margin of safety in hard assets. Leverage is substantial: $1.47B long-term debt plus a current ratio below 1.0 (0.976), meaning current liabilities exceed current assets. The company posted a net loss of $50.5M in FY2025 on $3.8B revenue. Free cash flow is a razor-thin $38.7M (1.0% FCF margin) on revenues nearly 100x that figure, making the P/FCF of 187x absurd. The DCF intrinsic value is negative (-$5.64/share) because the FCF base is too thin to support the debt load — the model itself confirms the equity is not covered by earnings power. The stock is at its 52-week HIGH of $139.30 — the precise opposite of a Schloss beaten-down bargain. The CEO sold shares in March 2026, a red flag on insider alignment. The investment thesis rests entirely on synergy narratives, integration execution, margin expansion forecasts, and poultry cycle tailwinds — all forward-looking growth stories, not verifiable hard assets. The balance sheet complexity from a cross-border merger (Marel was Icelandic, listed in Iceland/Nasdaq) adds exactly the accounting opacity Schloss avoided. The $200M buyback authorization is positive signaling but does not change the asset-quality picture. This is a post-merger industrial rollup trading at a 52-week high on synergy hopes — the antithesis of a Schloss statistical bargain.

Key points

Price-to-book of 1.62x already above tangible value; after stripping merger goodwill/intangibles tangible book is almost certainly negative
Current ratio below 1.0 (0.976) — current liabilities exceed current assets, signaling balance sheet stress
$1.47B long-term debt on only $38.7M FCF; debt-to-FCF ratio exceeds 37x — extremely leveraged relative to cash generation
Net loss of $50.5M in FY2025; negative ROE (-1.1%); ROIC only 2.5% — earnings power far below cost of capital
Stock is AT its 52-week high ($139.30) — Schloss bought at lows, not highs
DCF intrinsic value is negative (-$5.64/share base case) confirming no asset-based margin of safety
CEO insider selling in March 2026 — opposite of the insider alignment Schloss required

Red flags

Thesis is 100% dependent on synergy delivery, margin expansion, and poultry cycle continuation — no asset-based floor
Goodwill/intangibles from Marel acquisition dominate the balance sheet; tangible book value is not protective
Persistent tariff headwinds ($43M in 2025, $45M expected 2026) compress already thin margins with no hard asset cushion
Leverage ratio was 4.0x at merger close, improved to 2.9x but still well above Schloss comfort zone
Operating cash flow figure in fact base ($142.3M) appears to reference 2022, not 2025 — data inconsistency raises verification concern
FCF of $38.7M on $7.25B market cap implies Schloss-style yield of 0.5% — no income return while waiting for value recognition
Cross-border merger complexity (JBT + Marel hf.) creates exactly the accounting opacity Schloss systematically avoided

Fact base appendix

Price

last_close: 139.3
as_of: 2026-06-26
high_52w: 139.3
low_52w: 139.3
pct_below_52w_high: 0.0

Fundamentals

last_price: 139.3
market_cap: 7253044540
fifty_two_week_low: 113.67
fifty_two_week_high: 170.19
beta: 0.954
change_pct: 1.23547
currency: USD
sector: Industrials
industry: Industrial - Machinery
price_source: fmp_profile
bars: 1
entity: JBT Marel Corporation
fiscal_year: 2025
revenue: 3798200000
revenue_period: 2025-12-31
net_income: -50500000
net_income_period: 2025-12-31
operating_income: 189400000
operating_income_period: 2025-12-31
operating_cash_flow: 142300000
operating_cash_flow_period: 2022-12-31
capex: 103600000
capex_period: 2025-12-31
total_assets: 8191000000
total_assets_period: 2025-12-31
current_assets: 1583000000
current_assets_period: 2025-12-31
current_liabilities: 1622000000
current_liabilities_period: 2025-12-31
stockholders_equity: 4464000000
stockholders_equity_period: 2025-12-31
cash_and_equivalents: 167900000
cash_and_equivalents_period: 2025-12-31
long_term_debt: 1470000000
long_term_debt_period: 2025-12-31
shares_outstanding: 51982204
operating_margin: 0.0499
net_margin: -0.0133
roe: -0.0113
debt_to_equity: 0.3293
current_ratio: 0.976
roic: 0.0252
free_cash_flow: 38700000
fcf_margin: 0.0102
pe_ratio: -143.62
price_to_fcf: 187.42
price_to_sales: 1.91
revenue_cagr: 0.3367
revenue_cagr_years: 3
fundamentals_source: edgar_companyfacts
price_to_book: 1.62
earnings_yield: 0.0221
peg: -4.27

Filings reviewed

8-K (2026-05-19) https://www.sec.gov/Archives/edgar/data/1433660/000162828026036451/jbt-20260514.htm
8-K (2026-05-14) https://www.sec.gov/Archives/edgar/data/1433660/000162828026035145/jbt-20260514.htm
10-Q (2026-05-06) https://www.sec.gov/Archives/edgar/data/1433660/000162828026030756/jbt-20260331.htm
10-K (2026-03-02) https://www.sec.gov/Archives/edgar/data/1433660/000143366026000053/jbt-20251231.htm
10-Q (2025-11-04) https://www.sec.gov/Archives/edgar/data/1433660/000143366025000065/jbt-20250930.htm
10-K (2025-02-28) https://www.sec.gov/Archives/edgar/data/1433660/000143366025000009/jbt-20241231.htm

Other sources

[news] JBT Marel Corporation Announces Segment Realignment Effectiveness and Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call - Business Wire
[news] JBT Marel Corp (JBTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
[news] A Look At JBT Marel (JBTM) Valuation After Its Corporate Rebranding And Recent Share Price Weakness - Yahoo Finance
[news] A Look at JBT Marel Corp (JBTM) After 3.7% Decline -- GF Value $155.03 vs Price $119.00 - GuruFocus
[news] Insider Sell: CEO Brian Deck Sells Shares of JBT Marel Corp (JBTM) - GuruFocus
[news] JBT Marel Corp (JBTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
[news] JBT Marel Q1 2026 slides: 10% revenue growth, margins expand 210 bps - Investing.com
[news] JBT Marel Corp (JBTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[news] CORRECTING and REPLACING JBT Marel Corporation Declares Quarterly Dividend and Announces Share Repurchase Program - Business Wire
[news] JBT Marel authorizes $200M buyback, declares $0.10 quarterly dividend - TradingView
[news] This countertop juicer claims up to 50% more juice per fruit - Stock Titan
[news] JBT Marel Corp (JBTM) Institutional Confidence - TradingKey
[news] JBT Marel Corporation Announces First Quarter 2026 Earnings Release and Conference Call Schedule - Business Wire
[news] JBT Marel Corporation Reports First Quarter 2026 Results and Reiterates Full Year 2026 Guidance - Business Wire
[news] A Look At JBT Marel (JBTM) Valuation After Investor Day Synergy And Margin Updates - Yahoo Finance
[earnings_call] JBT Marel Corporation Q4 2025 Earnings Call

Generated 2026-07-17T20:18:36 · est. cost $1.40

What each investor thinks

AI & Disruption Referee (Christensen-style) Referee

pass · 72

Philip Fisher Growth

watch · 52

Michael Mauboussin Quality

watch · 52

Warren Buffett Quality

watch · 48

Ray Dalio Risk

watch · 48

Stanley Druckenmiller Risk

watch · 48

Peter Lynch Growth

watch · 48

Charlie Munger Quality

watch · 42

Forensic Short-Seller (Chanos/Einhorn-style) Referee

watch · 42

Joel Greenblatt Value

avoid · 32

Howard Marks Risk

avoid · 32

Chuck Akre Quality

avoid · 28

Valuation Referee (Damodaran-style) Referee

avoid · 28

Bruce Greenwald Value

avoid · 28

Benjamin Graham Value

avoid · 22

Seth Klarman Value

avoid · 22

Terry Smith (Fundsmith) Quality

avoid · 22

Walter Schloss Value

avoid · 18

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →